Vicor Technologies’ Selects Dell to Serve as Worldwide IT Hardware Partner for Its PD2i Analyzer(TM)

BOCA RATON, FL–(Marketwire – October 6, 2010) – David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Vicor has selected Dell’s Healthcare and Life Sciences division to serve as its worldwide hardware partner for the Company’s PD2i Analyzer™ and PD2i CA™ (Cardiac Analyzer). According to the terms of the agreement, Dell will create Vicor-labeled laptop computers specifically customized to Vicor’s specifications and package them for Vicor’s worldwide distribution. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events, including congestive heart failure patients for cardiac death resulting from arrhythmia or pump failure, diabetics for diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.

“Dell Healthcare and Life Sciences is proud to be chosen as Vicor’s worldwide IT solutions provider. Dell is committed to developing and supporting healthcare IT solutions to improve care and delivery,” stated Scott Jenkins, PhD, Vice President, Dell, Inc.

 “We’re thrilled to have Dell as our worldwide IT solutions partner. Dell’s well-established reputation for creating innovative technologies and business solutions, strong internal development capabilities, global reach, and consumer-centric approach make it the perfect worldwide IT solutions partner for Vicor,” stated Mr. Fater. 

“Given the growing amount of positive feedback we’re receiving from physicians and cardiologists using the PD2i Analyzer™ to enhance diagnosis of those at risk of cardiac death from arrhythmia or pump failure, as well as autonomic neuropathy, we’re extremely optimistic about the prospects for the PD2i Analyzer™ and PD2i CA™ worldwide. These diagnostics have enabled the physicians and cardiologists using them to use existing CPT codes for reimbursement, strengthened their ability to diagnose difficult to identify conditions, and enabled early, sometimes life-saving treatment,” Mr. Fater concluded.

About Vicor Technologies, Inc.
Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure.

Vicor anticipates developing additional applications utilizing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance in this release of name-brand institutions, such as Dell and the U.S. Army Institute for Surgical Research, does not constitute endorsement by these institutions of the information, products, or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a marketing claim for the PD2i CA™(Cardiac Analyzer) for testing patients for cardiovascular disease and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to obtain the necessary regulatory approvals to market in the People’s Republic of China; our ability to develop additional applications for the PD2i^®algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to successfully complete the normal range study for PD2i^®values; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-18

Click here to see all recent news from this company